EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Clinical Profile and Outcome of C3-Dominant Glomerulonephritis: Retrospective Study

Vishrut Khullar, Attur Ravindra Prabhu, Shankar Prasad Nagaraju, Dharshan Rangaswamy, Indu Ramachandra Rao, Srinivas Vinayak Shenoy, Mohan V. Bhojaraja, Gaurvi Piplani, Mahesha Vankalakunti

Kidney and Blood Pressure Research · 2026-01-12 · 51 (1) · 91-100

DOI: 10.1159/000550422 ↗
AbstractBibliografische Angaben

Abstract

Background: Complement 3 (C3)-dominant glomerulonephritis (GN) are rare diseases resulting from alternative complement pathway dysregulation; they include C3 glomerulopathy (C3G), paraprotein-associated GN, and C3-dominant infection-related GN (IRGN). To our knowledge, long-term follow-up studies of clinical profile and outcomes of this rare disorder are sparse. We studied kidney histopathology baseline findings, outcomes, treatment, and its complications of C3-dominant GN in our setting. Objectives: We studied the clinical, pathological profiles, and outcomes of patients with C3-dominant GN. Methods: This study was a single centre, retrospective, case record based observational study at a tertiary care hospital in Southern India. Consecutive patients of C3-dominant GN on kidney biopsy from 2013 to 2023 were included. Demography, laboratory and histopathological data, treatment and outcomes were studied. Results: Of 2,175 kidney biopsies, 141 (6.48%) showed C3-dominant GN; 74 (52.5%) C3G, 67 (47.5%) IRGN. Median age was 43 years (IQR 29–59.5), males 90 (63.8%). Preceding skin/throat infections were seen in 32/141 (22.7%). At presentation, median serum creatinine was 1.7 mg/dL (IQR: 1.2–3.6), eGFR

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →